The combination forms one of the largest dedicated healthcare investors globally, spanning pharma, medtech, diagnostics, and healthcare infrastructure across three continents.

The funding round positions Decart at the centre of the race to build AI systems capable of understanding and interacting with the physical world in real time.

The deal gives Regeneron access to Helicon peptide technology as pharma companies race to unlock previously “undruggable” intracellular targets.

Strengthening its structural heart pipeline, Boston Scientific expands into next-generation transcatheter aortic valve technology with an optional full acquisition pathway.

Bristol Myers Squibb’s expanding partnership strategy signals how China is evolving from a biotech sourcing market into a core pillar of global pharmaceutical R&D

Deal strengthens Bayer’s position in retinal disease and glaucoma as long-acting ophthalmology therapies attract growing investment.

A strategic move into bispecific antibodies as pharma races to redefine autoimmune treatment through targeted immune cell depletion and next-generation T cell engagers

Securing a next-generation JAK2 inhibitor strengthens Lilly’s position in rare blood cancers as pharma accelerates investment in mechanism-driven oncology assets.

Deal highlights accelerating pharma shift into rare metabolic disorders and obesity-adjacent indications as companies hunt for de-risked, high-value assets.

Merit Medical Systems has acquired View Point Medical through a merger aimed at strengthening its interventional solutions business and broadening its medical device portfolio.

Merck has agreed to acquire biotechnology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening its oncology pipeline ahead of the upcoming patent expiry of its blockbuster drug, Keytruda.